Shailendra U. Goud, Dr.Santosh Tarke, Dr.Gitanjali Chavan, Mr Vishal Sakhare, Ms Ashwini Gholkar, Mr. Narsuba D. Dhavle
Department of Pharmaceutics, SBSPMs College of Pharmacy, Ambajogai, Beed, Maharashtra, India. 431517
Development And Evaluation Of An Oral Liquid Dosage Form For Lumateperone, An Anti-Psychotic Drug
Authors
Abstract
The novel antipsychotic drug lumateperone has demonstrated encouraging efficacy in
treating a range of mental illnesses. However, some patient populations, such as those
with dysphagia or paediatric patients, may experience difficulties with its current
formulations, which are primarily in solid dose forms. The purpose of this study was to
develop and assess an oral liquid dosage form of lumateperone in order to alleviate this
limitation. In order to guarantee stability and improved bioavailability, solubility
improvement techniques and compatibility tests were employed during the formulation
process. To analyse formulation features, physicochemical characterisation was carried
out, which involved assessments of viscosity, pH, and drug content uniformity. Studies on
in vitro dissolution shed light on the kinetics of drug release and the effectiveness of the
formulation.To determine long-term viability, stability evaluations under various storage
settings were also conducted. The outcomes showed that lumateperone could be
successfully developed into an oral liquid formulation that is stable, bioavailable, and has
the desired physicochemical characteristics. Throughout the specified storage duration,
the formulation showed stable and uniform drug release profiles. This study offers a
practical and efficient lumateperone dosage option, marking a significant advancement in
pharmaceutical technology. It may enhance treatment adherence and therapeutic
outcomes, especially in patient populations for which solid dosage forms are unfeasible
or difficult to administer.